Needham analyst David Saxon raised the firm’s price target on iRhythm (IRTC) to $193 from $180 and keeps a Buy rating on the shares. The firm is citing its recent calls with a cardiologist and an electrophysiologist about ambulatory cardiac monitoring, including one doctor’s high volume practice considering moving over to iRhythm from BioTel, the analyst tells investors in a research note. Needham adds that the feedback suggests consumer monitoring technologies are likely more of a tailwind in the near-term, with iRhythm’s push into the PCP channel driving market expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies Poised for Growth: Buy Rating Affirmed Amid Strong Performance and Strategic Initiatives
- iRhythm price target raised to $183 from $167 at Citi
- iRhythm initiated with a Buy at BofA on market and margin expansion
- iRhythm initiated with a Buy at BofA
- Dayforce said in talks to be acquired, Soho House to go private: Morning Buzz